

Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/600,132
	Filing Date	06/19/03
	First Named Inventor	Miller and Richon
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
YV/	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
YV/	B1*	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X	
X	B2*	WO	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X	
X	B3*	WO	00/71703	Methylgene, Inc.	November 30, 2000	X	
Y	B4*	WO	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X	
y	B5*	WO	01/38322	Methylgene, Inc.	May 31, 2001	X	
Y	B6*	WO	01/70675	Methylgene, Inc.	September 27, 2001	X	
Y	B7*	WO	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X	
X	B8*	WO	02/30879	Prolifix Limited	April 18, 2002	X	
X	B9*	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
YV/	C1*	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
	C2*	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract 4611.
	C4*	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
	C5*	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
	C6*	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
X	C7*	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.

~~i did not receive~~

Date of Deposit: April 6, 2004

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
✓	C8*	Coffey et al. (2001). <i>Cancer Res.</i> 61 : 3591-3594.
✓	C9*	Cohen et al. (1999). <i>Anticancer Res.</i> 19 : 4999-5006.
✓	C10*	Cohen et al. (2002). <i>Anticancer Res.</i> 22 : 1497-1504.
✓	C11*	Curtin (2002). <i>Exp. Opin. Ther. Patents</i> 12 : 1375-1384.
✓	C12*	Dressel (2000). <i>Anticancer Res.</i> 20 : 1017-1022.
✓	C13*	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology Abstract No. 4602.
✓	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract No. 3195.
✓	C15*	Finnin et al. (1999). <i>Nature</i> 401 : 188-193.
✓	C16*	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> 98 : 87-92.
✓	C17*	Grunstein (1997). <i>Nature</i> 389 : 349-352.
✓	C18*	He et al. (2001). <i>J. Clin. Investigation</i> 108 : 1321-1330.
✓	C19*	Hockly et al. (2003). <i>Proc. Natl. Acad. Sci. USA</i> 100 : 2041-2046.
✓	C20*	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." <i>American Society of Clinical Oncology</i> , Abstract No. 344.
✓	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.
✓	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> 38 (Suppl. 7): 88, Abstract No. 286.
✓	C23*	Kim et al. (1999). <i>Oncogene</i> 18 : 2461-2470.
✓	C24*	Kohge et al. (1998). <i>Biochem. Pharmacol.</i> 56 : 1359-1364.
✓	C25*	Komatsu et al. (2001). <i>Cancer Res.</i> 61 : 4459-4466.
✓	C26*	Kouraklis and Theocharis (2002). <i>Curr. Med. Chem. Anti-Cancer Agents</i> 2 : 477-484.
✓	C27*	Lee et al. (2001). <i>Cancer Res.</i> 61 : 931-934.
✓	C28*	Lin et al. (1998). <i>Nature</i> 391 : 811-814.
✓	C29*	Mai et al. (2001). <i>OPPI Briefs</i> 33 : 391-394
✓	C30*	Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> 92 : 1210-1215.
✓	C31*	Marks et al. (2001). <i>Clinical Cancer Res.</i> 7 : 759-760.
✓	C32*	Marks et al. (2001). <i>Curr. Opin. In Oncology</i> 13 : 477-483.
✓	C33*	Marks et al. (2001). <i>Nature Reviews</i> 1 : 194-202.
✓	C34*	Miller et al. (2003). <i>J Med Chem.</i> 46 : 5097-5116.
✓	C35*	Munster et al. (2001). <i>Cancer Res.</i> 61 : 8492-8497.
✓	C36*	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742.
✓	C37*	Qui et al. (2000). <i>Mol. Biol. Cell</i> 11 : 2069-2083.
✓	C38*	Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> 93 : 5705-5708.
✓	C39*	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95 : 3003-3007.
✓	C40*	Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97 : 10014-10019.
✓	C41*	Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> 8 : 662-664.
✓	C42*	Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> 96 : 4592-4597.
✓	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and

x-Dist not receive


OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
MX	/	Radiation in Human Prostate Tumor Spheroids." <i>American Society of Clinical Oncology</i> , Abstract No. 105.
X	C44*	Stowell et al. (1995). <i>J. Med. Chem.</i> <u>38</u> : 1411-1413.
X	C45*	Su et al. (2000). <i>Cancer Res.</i> <u>60</u> : 3137-3142.
X	C46*	Suzuki et al. (1999). <i>J. Med. Chem.</i> <u>42</u> : 3001-3003.
X	C47*	Van Lint et al. (1996). <i>Gene Expression</i> <u>5</u> : 245-253.
X	C48*	Vrana et al. (1999). <i>Oncogene</i> <u>18</u> : 7016-7025.
X	C49*	Webb et al. (1999). <i>J. Biol. Chem.</i> <u>274</u> : 14280-14287.
X	C50*	Yoshida et al. (1990). <i>J. Biol. Chem.</i> <u>265</u> : 17174-17179.
X	C51*	Yoshida et al. (1995). <i>BioEssays</i> <u>17</u> : 423-430.
X	C52*	Zhou et al. (1999). <i>Gene</i> <u>233</u> : 13-19.
X	C53*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 1056-1061.
X	C54*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 14329-14333.
X	C55*	Zhou et al. (2001). <i>Proc. Natl. Acad. Sci. USA</i> <u>98</u> : 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/379,149, filed March 4, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Yevgeny Valenrod/	Date Considered	01/18/2008
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~Did not consider~~



Please type a plus sign (+) in this box ☐

PTO/SB (12-97)
OMB 0651-0031

Parent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Mod. Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/600,132
	Filing Date	June 19, 2003
	First Named Inventor	Miller
	Group Art Unit / Conf. No.:	1621 / 8627
	Examiner Name	Yevgeny Valenrod
	Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
YV/	A33	2005/0004007	01/06/05	Grant et al.	514	7	03/05/2003

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
YV/	C139	Rubartelli et al. (1995); "High Rates of Thioredoxin Secretion Correlate with Growth Arrest in Hepatoma Cells"; <i>Cancer Research</i> ; Vol. 55, pages 675-680.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Yevgeny Valenrod/	Date Considered	01/18/2008
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Modifying Form 1449/PTO	Application Number	10/600,132
		Filing Date	June 19, 2003
		First Named Inventor	Miller
		Group Art Unit / Conf. No.:	1621 / 8627
		Examiner Name	Yevgeny Valenrod
		Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
/YV/	A34	2004/0018968	01/29/04	Sgouros et al.	514	9	04/15/03
/YV/	A35	2006/0167103	07/27/06	Bacopoulos et al.	514	575	03/28/06
/YV/	A36	2006/0276547	12/07/06	Bacopoulos et al.	514	575	07/24/06
/YV/	A37	2007/0060614	03/15/07	Bacopoulos et al.	514	352	11/17/06

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Yevgeny Valenrod/	Date Considered	01/18/2008
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/ Please type a plus sign (+) in this box ☐



PTO/SB (12-97)
OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/600,132
	Filing Date	June 19, 2003
	First Named Inventor	Miller
	Group Art Unit / Conf. No.:	1621 / 8627
	Examiner Name	Yevgeny Valenrod
	Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
YV/	C140	Phase I clinical trial of oral suberoylanilide hydroxamic acid - SAHA (msk390) in patients with advanced solid tumors and hematologic malignancies; first patient dosed in August 2001 at Memorial Sloan Kettering Cancer Center. SAHA gelatin capsules containing SAHA and excipients were administered to patients. The SAHA was prepared according to methods in Example 1 of U.S. application 10/379,149.
YV/	C141	Copy of February 2, 2007 Office Action in USSN 10/379,149.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Yevgeny Valenrod/	Date Considered	01/18/2008
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.